Acetylator phenotype in patients with lung carcinoma--a negative report.
Fractional acetylation of plasma sulphadimidine 6 h after dosing with 40 mg/kg metabolically active mass (p.o.) was measured in 53 patients with primary lung carcinoma and in 31 controls. Sixty percent of all tumour patients and 58% of controls were slow acetylators. There was no statistical evidence (P greater than 0.5) of association between acetylator phenotype and lung carcinoma.
D000107:Acetylation; D000123:Acetyltransferases / Q000235:genetics*; D000368:Aged; D001191:Arylamine N-Acetyltransferase / Q000235:genetics* / Q000378:metabolism; D002294:Carcinoma, Squamous Cell / Q000097:blood / Q000201:enzymology / Q000235:genetics; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood / Q000201:enzymology* / Q000235:genetics; D008297:Male; D008875:Middle Aged; D010641:Phenotype; D013418:Sulfamethazine / Q000097:blood
D013418:Sulfamethazine; D000123:Acetyltransferases; C047057:isoniazid acetyltransferase; D001191:Arylamine N-Acetyltransferase